It is unclear whether frequently used cutoff values for outcome measures defining minimal clinically important differences (MCIDs) can accurately identify meaningful deterioration in chronic inflammatory demyelinating polyneuropathy (CIDP). We used data from the immunoglobulin overtreatment in CIDP (IOC) trial, in which 60 clinically stable patients with CIDP were randomized to intravenous immunoglobulin (IVIg) withdrawal or continuation. We calculated change scores of the Inflammatory Rasch-Built Overall Disability Scale (I-RODS), grip strength, and Medical Research Council-sum score (MRC-SS) and classified visits based on a treatment anchor (ie, decision to restart/increase treatment after reaching a predefined early endpoint of deteriora...
Outcome measures are recommended in the management of chronic inflammatory demyelinating polyneuropa...
Outcome measures are recommended in the management of chronic inflammatory demyelinating polyneuropa...
Defining long-term outcomes in chronic inflammatory demyelinating polyneuropathy (CIDP) has been com...
It is unclear whether frequently used cutoff values for outcome measures defining minimal clinically...
INTRODUCTION The comparative value and suitability of outcome measures are uncertain in chronic i...
Introduction: The comparative value and suitability of outcome measures are uncertain in chronic inf...
Clinical trials in chronic inflammatory demyelinating polyneuropathy (CIDP) often assess efficacy us...
This narrative review provides an overview of specific outcomes that are appropriate for chronic inf...
Background The ICE trial demonstrated the efficacy of immune globulin intravenous (IGIV-C) over plac...
INTRODUCTION The use of outcome measures is recommended for chronic inflammatory demyelinating po...
Outcome measures are recommended in the management of chronic inflammatory demyelinating polyneuropa...
Outcome measures are recommended in the management of chronic inflammatory demyelinating polyneuropa...
Defining long-term outcomes in chronic inflammatory demyelinating polyneuropathy (CIDP) has been com...
It is unclear whether frequently used cutoff values for outcome measures defining minimal clinically...
INTRODUCTION The comparative value and suitability of outcome measures are uncertain in chronic i...
Introduction: The comparative value and suitability of outcome measures are uncertain in chronic inf...
Clinical trials in chronic inflammatory demyelinating polyneuropathy (CIDP) often assess efficacy us...
This narrative review provides an overview of specific outcomes that are appropriate for chronic inf...
Background The ICE trial demonstrated the efficacy of immune globulin intravenous (IGIV-C) over plac...
INTRODUCTION The use of outcome measures is recommended for chronic inflammatory demyelinating po...
Outcome measures are recommended in the management of chronic inflammatory demyelinating polyneuropa...
Outcome measures are recommended in the management of chronic inflammatory demyelinating polyneuropa...
Defining long-term outcomes in chronic inflammatory demyelinating polyneuropathy (CIDP) has been com...